Medical trials are currently being conducted at Alivation—this is your chance to help science and medicine. Study-related exams, tests and medication will be provided at no cost, and you may be compensated for your time.

Review the open research studies below and apply for the one(s) you qualify for. Bookmark this page and check back often, as studies are often updated and we’re always recruiting qualified candidates. Check out our list of studies or contact us with any questions. Participation in all research is voluntary and not everyone may qualify. If you are interested in learning how you can assist in scientific research, or if you’d like to participate in a study for a condition not listed, please call 402.476.6060, option 4.

If you would like to submit research study ideas, or if you have any questions about studies, please send an email to research@alivation.com. 

CURRENT PHARMACEUTICAL RESEARCH TRIALS:
  • Phase 2/3 study evaluating AXS-05 (bupropion hydrochloride and dextromethorphan hydrobromide monohydrate) for individuals with treatment-resistant depression
  • Duration of the study is 3 months, consisting of 10 visits to the clinic
  • Must be currently experiencing moderate to severe symptoms of depression
  • History of inadequate response to an antidepressant
  • Compensation for your time and travel is offered
    1. Phase 3 study evaluating Cariprazine as an adjunct to an antidepressant for patients diagnosed with Major Depressive Disorder or who are experiencing symptoms of depression
    2. Duration of the study is 2 months, consisting of 7 visits to the clinic
    3. Must be currently experiencing moderate to severe symptoms of depression
    4. Must be currently on an antidepressant and having an inadequate response to the treatment OR had an inadequate response to an antidepressant during the current depressive episode (not exceeding over 18 months ago)
    5. Compensation for your time and travel is offered
    1. Phase 3 study evaluating Escitalopram in children and adolescents with Generalized Anxiety Disorder
    2. Duration of the study is 10 weeks, consisting of 8 visits to the clinic

3. Must be experiencing anxiety symptoms that interfere with home, school, or social life

  • Phase 3 clinical study of Adjunctive Molindone Hydrochloride ER for the treatment of Impulsive aggression in pediatric patients with ADHD.
  • Duration of the study is 13 weeks, consisting of 7 visits.
  • Currently on a monotherapy treatment for ADHD.
  • BMI less than 99th.
  • Subject’s parent(s) or legally authorized representative (LAR) must be able to provide informed consent and comply with study requirements.
  • Compensation for your time and travel is offered.
    1. Phase 3 clinical study of Adjunctive Molindone Hydrochloride ER for the treatment of Impulsive aggression in adolescent patients with ADHD.
    2. Duration of the study is 2 months, consisting of 8 visits.
    3. Currently on a monotherapy treatment for ADHD.
    4. BMI is more than 25th and less than 99th percentile for age and gender.
    5. Subject’s parent(s) or legally authorized representative (LAR) must be able to provide informed consent and comply with study requirements.
    6. Compensation for your time and travel is offered.
    1. Phase 3 clinical study of Centanafadine Sustained-release tablets in Adults diagnosed with ADHD or experiencing symptoms of ADHD
    2. Duration of the study is 11 weeks, consisting of 9 visits to the clinic.
    3. Currently experiencing symptoms of ADHD that are interfering with school, work, or relationships, or homelife.
    4. BMI has to be between 18-40.
    5. Compensation for your time and travel is offered.
    1. Non-interventional study examining the real-life effectiveness of Trintellix in patients with major depressive disorder
    2. Looking for individuals about to start Trintellix (they cannot already be taking it)
    • Phase 2b study evaluating Ecopipam in Children and Adolescents with Tourette’s Syndrome
    • Duration of study is 17 weeks, consisting of 11 visits to the clinic
    • Must experiencing motor and/or vocal tics that cause distress or impairment with work, school, or social function
    • Compensation for your time and travel is offered
        1. Phase 3 study evaluating TEV-50717 (Deutetrabenzaine) for the treatment of dyskinesia in cerebral palsy in children and adolescents
        2. Duration of the study is 17 weeks, consisting of 14 visits to the clinic
        3. Must have involuntary movements (dyskinesia) with chorea as the predominant movement problem (will be assessed at the screening visit)
        4. Must be able to swallow study medication
        5. Must have dyskinesia as the predominant movement disorder
  1. Non-interventional study for adults 19 and older
  2. Must have a diagnosis of Schizophrenia and about to start one of four atypical long acting injectables – Abilify Maintena, Aristada, Invega Sustenna, or Risperdal Consta
  1. Phase 3b study evaluating Abilify MyCite in adults with schizophrenia
  2. Duration of the study is 8 months, consisting of 9 visits to the clinic
  • Must possess a smartphone and willing to download the Abilify MyCite app
  1. Must be currently taking an oral atypical antipsychotic medication for 6 months or longer
  2. Must have had an inpatient hospitalization for schizophrenia within the last 4 years
    • Phase 4 study evaluating Guanfacine Hydrochloride Prolonged-release in Children and Adolescents with Attention-deficit/Hyperactivity Disorder (ADHD)
    • Duration of the study is 52 weeks, consisting of 17 visits to the clinic
    • Must be experiencing symptoms of ADHD which cause distress or impairment with work, school, or social function
    • Compensation for your time and travel is offered
    • Phase 3 study evaluating Levomilnacipran in adolescents with major depressive disorder
    • Duration of the study is 10 weeks, consisting of 9 visits to the clinic
    • Must be experiencing symptoms of depression which cause distress or impairment with work, school, or social function
    • Compensation for your time and travel is offered
      • Phase 2/3 study evaluating AXS-05 for the treatment of agitation in subjects with dementia of the Alzheimer’s type
      • Duration of the study is 8 weeks, consisting of 7 visits to the clinic
      • Must be experiencing symptoms of Alzheimer’s or been diagnosed with Alzheimer and also experiencing agitation
      • Must have a caregiver who is willing to attend study visits
      • Compensation for your time and travel is offered
  • Phase 3 study evaluating Brexpiprazole in Adults with Post-traumatic Stress Disorder
  • Duration of the study is 16 weeks, consisting of 11 visits to the clinic
  • Must be experiencing symptoms of PTSD which cause distress or impairment with work, school, or social function
  • The traumatic event had to have occurred after the age of 16.
  • Traumatic event had to occur within the past 9 years
  • Compensation for your time and travel is offered
      • Study is evaluating VNS Therapy System as Adjunctive therapy with people with treatment-resistant depression
      • Duration of the study is 60 months, consisting of 22 visits to the clinic
      • Must be experiencing symptoms of depression and have not received benefit from at least one antidepressant treatment
      • Compensation for your time and travel is offered
CURRENT TMS RESEARCH TRIALS:
        1. Randomized clinical study of deep transcranial magnetic stimulation (dTMS) for PTSD
        2. Duration of the study is 9 weeks, consisting of 14 visits to the clinic
        3. Must have symptoms of PTSD that cause distress and impairment in at least one area of life (ex: work, school, home, social)
        4. Cannot have significant hearing loss, seizures, severe headaches, or any unstable physical disease
        5. Compensation for your time and travel is offered
Upcoming Studies

More details on this study are coming soon.

Our dedicated research staff is certified to conduct clinical trials according to Good Clinical Practices (GCP), adhering to all written standard operating procedures (SOPs) and HIPPA regulations.